|
CHANGCHUN, China, Aug. 29, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. ("JCBio"), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with JCBio's local expertise, the partnership empowers researchers and clinicians while strengthening South Korea's role as a regional leader in genomics and biotechnology.
Empowering South Korea's Genomics Ecosystem
In an era where multi-omics research is reshaping healthcare, the collaboration between MGI Tech and JCBio marks a significant milestone in strengthening South Korea's genomics ecosystem. By combining MGI's proprietary short-read and long-read sequencing technologies, the initiative equips JCBio's laboratories with end-to-end multi-omics capabilities, enabling researchers to tackle complex biological challenges with greater precision and efficiency.
Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies, advance integrated multi-omics analyses, explore novel sequencing applications, accelerate precision medicine, clinical translation, and AI-driven data insights—positioning the laboratory as a local hub for cutting-edge genomic research and multi-omics innovation.
The DCS Lab Initiative: Driving Frontier Science
Launched in 2023, MGI's DCS Lab Initiative was established to empower international laboratories with comprehensive sequencing solutions. Named after MGI's three core technologies—DNA genomics, Cell omics, and Spatial omics—the DCS Lab initiative is the company's first global program targeting international laboratories with a focus on frontier science. It represents MGI's unique capability within the industry to provide end-to-end products for applications ranging from DNA genomics to cell omics and spatial omics.
The initiative has already enabled pioneering research worldwide. At MGI's Customer Experience Centre (CEC) in Australia, technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer, medicine, and agriculture. Building on this success, MGI is now extending the program to South Korea in collaboration with JCBio—reinforcing the nation's role as a key hub in Asia's rapidly growing biotech ecosystem.
Executive Perspectives
"We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation," said Dr. Roy Tan, Director of MGI Northeast Asia. "With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea's research community with the tools to drive frontier science and improve human health."
JCBio's leadership emphasized the transformative nature of the collaboration:
"This partnership with MGI is a game-changer for South Korea's research community," added JaeChan Yoo, CEO of JCBio. "By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea's growing role in global genomics research."
About JCBio
Founded in 2005, JCBio has established itself as a key provider of research and diagnostic products in South Korea's life sciences sector, with a mission to enhance longevity and improve quality of life.
For more information, please visit: https://jcbio.co.kr/company/greeting.php#
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.
For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
CHANGCHUN, China, Aug. 29, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. ("JCBio"), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with JCBio's local expertise, the partnership empowers researchers and clinicians while strengthening South Korea's role as a regional leader in genomics and biotechnology.
Empowering South Korea's Genomics Ecosystem
In an era where multi-omics research is reshaping healthcare, the collaboration between MGI Tech and JCBio marks a significant milestone in strengthening South Korea's genomics ecosystem. By combining MGI's proprietary short-read and long-read sequencing technologies, the initiative equips JCBio's laboratories with end-to-end multi-omics capabilities, enabling researchers to tackle complex biological challenges with greater precision and efficiency.
Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies, advance integrated multi-omics analyses, explore novel sequencing applications, accelerate precision medicine, clinical translation, and AI-driven data insights—positioning the laboratory as a local hub for cutting-edge genomic research and multi-omics innovation.
The DCS Lab Initiative: Driving Frontier Science
Launched in 2023, MGI's DCS Lab Initiative was established to empower international laboratories with comprehensive sequencing solutions. Named after MGI's three core technologies—DNA genomics, Cell omics, and Spatial omics—the DCS Lab initiative is the company's first global program targeting international laboratories with a focus on frontier science. It represents MGI's unique capability within the industry to provide end-to-end products for applications ranging from DNA genomics to cell omics and spatial omics.
The initiative has already enabled pioneering research worldwide. At MGI's Customer Experience Centre (CEC) in Australia, technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer, medicine, and agriculture. Building on this success, MGI is now extending the program to South Korea in collaboration with JCBio—reinforcing the nation's role as a key hub in Asia's rapidly growing biotech ecosystem.
Executive Perspectives
"We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation," said Dr. Roy Tan, Director of MGI Northeast Asia. "With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea's research community with the tools to drive frontier science and improve human health."
JCBio's leadership emphasized the transformative nature of the collaboration:
"This partnership with MGI is a game-changer for South Korea's research community," added JaeChan Yoo, CEO of JCBio. "By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea's growing role in global genomics research."
About JCBio
Founded in 2005, JCBio has established itself as a key provider of research and diagnostic products in South Korea's life sciences sector, with a mission to enhance longevity and improve quality of life.
For more information, please visit: https://jcbio.co.kr/company/greeting.php#
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.
For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MGI Tech and JCBio Announce Collaboration on DCS Lab Project to Advance Multi-Omics Innovation in South Korea
NEW YORK, Dec. 19, 2025 /PRNewswire/ -- CamScanner today released its 2025 Annual Summary, marking a year of accelerated product innovation, strengthened AI capabilities, and continued global expansion. With more than 300 million users worldwide, the platform has further solidified its position as one of the most trusted tools for scanning and intelligent document management.
In 2025, CamScanner introduced several key enhancements that redefined efficiency in digital workflows. Building on its strong scanning foundation, the platform launched Auto Page-Turn Capture, a feature that recognizes page flips and captures images automatically. This significantly improves the speed and convenience of digitizing full books and multi-page documents. CamScanner also unveiled the Watermark Camera, which embeds real-time timestamps and location data into photos to ensure authenticity and traceability—an essential function for legal documentation, fieldwork, compliance reporting, and other professional scenarios requiring verifiable visual records.
Another major milestone was the upgrade of CS AI. The enhanced system now delivers more accurate image optimization while improving the clarity, structure, and tone of scanned text. Its refined Q&A and study-assist capabilities enable faster information extraction and smarter learning support, offering users a more seamless and intelligent end-to-end document experience.
CamScanner's brand influence continued to grow globally. The app was featured as Apple Store's "App of the Day" across more than 20 countries and regions, including major markets in Europe and Southeast Asia, and ranked No. 1 in the Productivity category on the App Store in 84 countries and regions. It also received strong international recognition, being named "Best Document Scanning App of 2025" by TechRadar and "Best Mobile Scanning and OCR App" by Zapier, reinforcing its leadership across the global productivity landscape.
Throughout the year, CamScanner supported a wide range of professional and everyday scenarios. Lawyers used the Watermark Camera and precision scanning to securely digitize case files. Students and teachers built searchable digital study libraries, aided by CS AI's instant problem-solving capabilities. Sales professionals streamlined client documentation and contract processing, while researchers restored historical materials with enhanced image clarity. In workplaces, employees relied on CamScanner to accelerate routine document submission, format conversion, and cross-device collaboration.
With continuous advancements and an expanding global community, CamScanner remains committed to delivering smarter, more reliable solutions that empower users across industries and drive the evolution of digital productivity.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CamScanner Releases 2025 Annual Summary Highlighting Breakthrough Innovation and a Global User Base Exceeding 300 Million
